All In Biotech

Drug Trial Radar · NCT07929740

Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS

Relative Bioavailability and Bioequivalence Study of Ziftomenib Drug Products in Participants With Relapsed/Refractory AML With NPM1 Mutation, or With Relapsed/Refractory AML or MDS With Mutations Associated With MEIS1 Overexpression

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Feb 28, 2029

Study completion Feb 28, 2029

Sponsor

Lead sponsor
Kura Oncology, Inc.Industry
Sponsor type
Industry
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the pharmacokinetics (PK) of ziftomenib drug products to inform relative bioavailability (rBA) and bioequivalence (BE) assessments.

Conditions

  • Myelodysplastic Syndrome (MDS)/AML
  • Myeloid Leukemia, Acute

Interventions

  • ZiftomenibDrug

    Oral Formulation 1

  • ZiftomenibDrug

    Oral Formulation 2

  • ZiftomenibDrug

    Oral Formulation 3

  • ZiftomenibDrug

    Oral Formulation 4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A, B and C)Time frame: During the first 56 days of ziftomenib
  2. To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B)Time frame: During the first 56 days of ziftomenib
  3. To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A, B and C)Time frame: During the first 56 days of ziftomenib
  4. To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B)Time frame: During the first 56 days of ziftomenib
  5. To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B)Time frame: During the first 56 days of ziftomenib

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.